**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 68919

**Manuscript Type:** META-ANALYSIS

**Generic and disease-specific health-related quality of life in patients with Hirschsprung disease: A systematic review and meta-analysis**

Huizer V *et al*. Quality of life in Hirschsprung disease

Veerle Huizer, Naveen Wijekoon, Daniëlle Roorda, Jaap Oosterlaan, Marc A Benninga, LW Ernest van Heurn, Shaman Rajindrajith, Joep PM Derikx

**Veerle Huizer, Daniëlle Roorda, LW Ernest van Heurn, Joep PM Derikx,** Department of Pediatric Surgery, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam Reproduction and Development, Amsterdam 1105 AZ, Netherlands

**Naveen Wijekoon,** Department of Surgery, University of Colombo and Department of Paediatric Surgery, Lady Ridgeway Hospital for Children, Colombo 00800, Sri Lanka

**Shaman Rajindrajith,** Department of Pediatrics, Lady Ridgeway Hospital for Children, Colombo 00800, Sri Lanka

**Daniëlle Roorda, Jaap Oosterlaan, Marc A Benninga,** Department of Pediatrics, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Emma Neuroscience Group, Amsterdam Reproduction and Development, Amsterdam 1105 AZ, Netherlands

**Author contributions:** Huizer V, Roorda D, Derikx JPM and Rajindrajith S designed the study and designed data collection; Huizer V and Wijekoon N performed study selection, performed study quality assessment, collected data, carried out the initial analyses, drafted the initial manuscript and revised the manuscript; Roorda D supervised data collection, statistical analyses and critically reviewed the manuscript; Derikx JPM, Rajindrajith S, Benninga MA, van Heurn LWE and Oosterlaan J reviewed the manuscript; all authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

**Corresponding author: Danielle Roorda, MD, MSc, Research Scientist,** Department of Pediatric Surgery, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam Reproduction and Development, Meibergdreef 9, Amsterdam 1105 AZ, Netherlands. d.roorda@amsterdamumc.nl

**Received:** June 9, 2021

**Revised:** October 15, 2021

**Accepted: February 22, 2022**

**Published online:**

**Abstract**

BACKGROUND

Patients with Hirschsprung disease (HD) are at risk of persistent constipation, fecal incontinence or recurrent enterocolitis after surgical treatment, which in turn may impact physical and psychosocial functioning. Generic health-related quality of life (HRQoL) and disease-specific health-related quality of life are relevant outcome measures to assess the impact of HD on the QoL of these patients.

AIM

To summarize all available evidence on HRQoL of patients with HD after surgery and the impact of possible moderating factors.

METHODS

Pubmed, Web of Sciences, PsycInfo and Embase were searched with search terms related to ‘Hirschsprung disease’, ‘Pediatrics’ and ‘Quality of life’. Mean and standard deviation of generic HRQoL overall and domain scores were extracted from each study, as well as data describing potential factors associated with QoL. Random effect models were used for meta-analytic aggregation of generic HRQoL scores. Meta-regression was used to assess the relationship between patient and clinical characteristics and generic HRQoL. Disease-specific HRQoL outcomes of patients with HD were systematically reviewed.

RESULTS

Seventeen articles were included in the systematic review (*n* = 1137 patients) and 15 in the quantitative meta-analysis (*n* = 1024 patients). Four studies reported disease-specific HRQoL. Patient’s age ranged between 0 and 21 years. Meta-analytic aggregation showed a non-significantly impaired generic HRQoL (*d* = -0.168 [95%CI: -0.481; 0.145], *P* = 0.293, *I²* = 94.9) in patients with HD compared to healthy controls. Physical (*d* = -0.042 [95%CI: -0.419; 0.335], *P* = 0.829, *I²* = 95.1), psychosocial (*d* = -0.159 [95%CI: -0.458; 0.141], *P* = 0.299, *I*² = 93.6) and social HRQoL (*d* = -0.092 [95%CI: -0.642; 0.457], *P* = 0.742, *I²* = 92.3) were also not significantly lower compared to healthy controls. There was no relation between health-related outcomes and the sex of the patients and whether generic HRQoL was measured by parental proxy or self-report. Disease-specific complaints of patients with HD impaired physical HRQoL, but not psychosocial and social HRQoL.

CONCLUSION

In this systematic review and meta-analysis, no evidence was found for impaired generic HRQoL in patients with HD compared to healthy controls, neither for moderating effects of sex, parental proxy or self-report.

**Key Words:** Hirschsprung disease; Health-related quality of life; Meta-analysis; Systematic review; Pediatrics

Huizer V, Wijekoon N, Roorda D, Oosterlaan J, Benninga MA, van Heurn LWE, Rajindrajith S, Derikx JPM. Generic and disease-specific health-related quality of life in patients with Hirschsprung disease: A systematic review and meta-analysis. *World J Gastroenterol* 2022; In press

**Core Tip:** Patients with Hirschsprung disease are at risk of constipation, fecal incontinence or enterocolitis after surgery, which in turn may negatively impact physical and psychosocial functioning. In this meta-analysis of 17 available studies representing 1137 patients, we found no evidence that patients with Hirschsprung disease have lower generic health-related quality of life (HRQoL) compared to healthy controls. Generic HRQoL was not dependent of sex of patients and not dependent of whether quality of life was measured by self-report or by parental proxy-report. Disease-specific complaints of patients with HD impaired physical HRQoL, but not psychosocial and social HRQoL.

**INTRODUCTION**

Hirschsprung disease (HD) is a congenital anomaly with an incidence of approximately 1 in 5000 live births, characterized by a lack of ganglionic cells in the enteric nervous system of a distal segment of the gastrointestinal tract[1-3]. Affected neonates typically present with failure to pass meconium followed by obstructive defecation problems[2]. In most patients, the aganglionosis extends no further proximally than the rectum or rectosigmoid, which is defined as short segment disease[4]. In some patients aganglionosis is more severe and extends further proximal, with extension to the complete colon or small intestine in 5%-10%[5]. Definitive surgical management for HD involves resection of the affected bowel segment and restoration of bowel continuity with a straight anastomosis or a pouch[5]. Even after surgical resection of the aganglionic segment, it may take years for patients to acquire normal bowel function and continence[2]. In addition, patients are at risk of long-term disease-specific problems, including persistent constipation (11%-16%)[1,6-11], fecal soiling or incontinence (7%-48%)[1,6-11] or recurrent episodes of enterocolitis (0%-33%)[1,6-11]. HD can therefore be regarded as a chronic bowel condition, which may severely impact daily functioning.

According to the WHO, quality of life (QoL) can be described as a person’s subjective evaluation of their position in life in the context of their culture and value systems[12]. Health-related QoL (HRQoL) describes a person’s subjective evaluation of their physical and mental health[13]. HRQoL can be considered as a multidimensional construct and its evaluation generally relies on the patient’s subjective evaluation of well-being and functioning in different aspects and dimensions of well-being and functioning, together resulting in an overall construct[14]. Instruments that measure HRQoL can be generic and disease-specific[15].Instruments that measure generic HRQoL can be used to measure HRQoL both in healthy and ill children and can be used for the comparison of HRQoL accros different conditions and settings, whereas disease-specific HRQoL instruments only measure HRQoL in patients with a certain condition, and are typically better in detecting changes in HRQoL over time[15].For patients with HD the disease-specific questionnaire HAQL (Hirschsprung disease / Anorectal malformation Quality of Life) has been developed[4].

There is growing interest in HRQoL of patients with HD, as shown by the increasing number of studies reporting on generic and disease-specific HRQoL in these patients. The current body of evidence is inconsistent about whether HRQoL and functional outcomes are lower in patients with HD compared to healthy controls[6,7,11,15,16]. The available literature suggests evidence for several factors to be related to HRQoL and functional outcomes, including patient age[1,3,17], the use of parental proxy *vs* self-report[18], length of aganglionosis[19], type of surgical procedure and anastomosis technique used in surgery[20], postoperative complications[20-25], presence of a stoma[26-28] and syndromal anomalies[29]. Thus far the available evidence on generic HRQoL and disease-specific HRQoL among HD patients has not been systematically reviewed and aggregated precluding clear conclusions to be drawn.

The primary aim of this systematic review and meta-analysis was to summarize all available evidence on differences in generic health-related quality of life between patients with HD and normative data. Secondary aim was to summarize available evidence on disease-specific health-related quality of life of patients with HD. Third aim was to study patient and clinical factors that could explain differences in generic HRQoL between patients and normative data, including sex, age, the use of parental proxy *vs* self-report, length of aganglionosis, operation technique, postoperative complications, presence of stoma and syndromal anomalies using meta-regression.

**MATERIALS AND METHODS**

This meta-analysis was conducted according to the PRISMA guidelines[30].

***Eligibility criteria***

The following eligibility criteria were used: (1) The sample consisted of patients diagnosed with HD and a medical history of surgical resection of the affected bowel segment; (2) The majority of the patients included in the study had the age between 0 and 18 years old at assessment; (3) Generic HRQoL was measured as outcome; (4) Studies had an observational or case-control design and used HRQoL measures for which normative data is available, or compared patients with HD with normative data or a healthy control group; and (5)The study reported original data, with a minimum sample size arbitrarily set at *n* = 10. Studies were excluded if the full text was only available in a language other than English.

***Search and selection***

Pubmed, Web of Sciences, PsycInfo and Embase were searched using entry terms related to: ‘Hirschsprung disease’, ‘Pediatrics’ and ‘Quality of life’. The full search strategy can be found in the Supplementary Material(Appendix 1). Reference lists of included articles were checked for additional studies matching our eligibility criteria. Screening of title, abstract and full-text of the studies was performed by two independent researchers (N.W. and V.H.) using the online software Covidence[31]. Initial disagreements on study selection were discussed and in case of persistent conflicting judgement, a third party (D.R.) was consulted to reach consensus.

***Data extraction***

As primary outcome measurement, the mean scores and corresponding standard deviation of generic HRQoL were extracted by one researcher (V.H.). Additionally, the following characteristics were extracted from each study: domain scores (physical, psychosocial and social HRQoL), publication year, study design, sample size, type of questionnaire used to assess HRQoL, mean age of patients, percentage of male patients , percentage of measurements with parental proxy and self-report, percentage of patients with short aganglionic bowel segment, type of surgery (percentage of patients operated using the Duhamel technique and percentage of patients operated using Transanal Endorectal Pull-through [TEPT] technique), percentage of patients with postoperative complications, percentage of patients with a stoma present, and percentage of patients who had a syndromal comorbidity. If required data was not reported, authors were requested by email to provide additional data. In case of non-response of the author after one reminder and when available data was not sufficient for adequate analysis, the study was excluded from the analyses. In case a study reported median generic HRQoL scores, these were recalculated to mean scores[32,33], or else the median was considered to be the best approximation of the mean. For those studies that did not include a control group, questionnaire specific local age- and sex-matched normative values were used and compared with the reported outcomes of patients with HD[34-39].

***Quality assessment***

The Newcastle-Ottawa Scale (NOS) was used to assess quality of the studies in this meta-analysis[40]. According to the manual, we adapted the scoring system to our study design. A detailed description of the adjustment can be found in the Supplementary Material(Appendix 2). The included studies were rated on a 9-point rating scale by two of the authors (N.W. and V.H.), based on aspects of participant selection (4 points), group comparability (2 points) and outcome assessment (3 points). Quality of studies was considered good, fair and poor using AHRQ (Agency for Health Research and Quality) criteria[41]. Rating discrepancies were resolved by consensus.

***Statistical analysis***

Statistical analysis was performed using CMA (Comprehensive Meta-Analysis)[42]. The standardized mean difference (expressed as Cohen’s d) of generic HRQoL and domain scores between patients with HD and healthy control or normative populations were calculated for each study. Effect sizes *d* of 0.2, 0.5 and 0.8 were taken as thresholds to define small, medium and large effects, respectively[43]. For all outcomes, heterogeneity of effect sizes was quantified using *I²* statistic. Heterogeneity was regarded small (*I²* ≤ 0.25), moderate (0.25 < *I²* < 0.50) or large (*I²* ≥ 0.50), according to Higgins[44]. In case of moderate or large heterogeneity, random effects models were used.

Individual study findings were presented in forest plots and aggregated into summary estimates of standardized mean differences for: (1) Generic HRQoL; (2) Physical HRQoL; (3) Psychosocial HRQoL; and (4) Social HRQoL. In case a study reported on more than one outcome, within study findings were pooled into an weighted estimate on these predefined domains, using a built-in function in CMA. A detailed description of which items in different HRQoL-measurements were pooled into domain scores can be found in the Supplementary Material(Appendix 3). In case a study reported no generic HRQoL score, the mean of at least two reported domain scores was considered as a reflection of the generic HRQoL.

Publication bias analysis included visual inspection of funnel plots and calculation of Egger’s intercept. Robustness of the calculated aggregated effect sizes against the influence of publication bias was assessed with fail safe N. An effect was considered robust when fail safe N > 5k+10[45].

To explore sources of heterogeneity, subgroup analyses were performed to assess differences in each of the HRQoL outcomes between: (1) Studies reporting on different age groups ([< 12 years], [12-16 years] and [16+ years]); (2) Studies using different questionnaires to assess HRQoL (for example assessment by the CHQ *vs* PedsQL); (3) Studies that used a control group and studies that used normative reference data; and (4) Studies that reported generic HRQoL scores and studies in which a generic score was constructed from domain scores. Sensitivity analysis was used to explore the influence of study quality on summary estimates of all HRQoL outcomes. The moderating effect of sex and parental proxy *vs* self-report on generic HRQoL scores was explored using univariate meta-regression which was only conducted in case of at least 10 observations.

***Narrative analysis of disease-specific HRQoL***

Since the HAQL is a disease-specific questionnaire, a quantitative comparison with healthy controls could not be made. Designating one cohort as reference group is random and was therefore not considered to be meaningful in this context. Thus pooled summary estimates for the HAQL scores were made and findings within individual studies, in term of domains on which relatively lower disease-specific HRQoL scores were reported, were narratively described.

**RESULTS**

The flowchart of the study search and selection process is provided in Figure 1. Our search yielded 334 unique records, of which 17 studies (*n* = 1141 patients) were included in the current systematic review and of which 15 studies contributed data to the meta-analysis.

***Study characteristics***

Table 1 summarizes the characteristics of the 17 included studies. Of the 17 studies, 15 studies measured generic HRQoL and four studies measured disease-specific HRQoL. The PedsQL was most frequently used to assess generic HRQoL (in 10 of 15 studies). All four studies used the HAQL to assess disease-specific HRQoL. Four out of 17 studies used a controlled study design. Patients’ ages ranged from 0 to 21 years.

***Generic Health-related Quality of Life***

**Generic HRQoL:** Fifteen (15) studies (*n* = 1024 patients) were included in the meta-analysis comparing patients with HD to normative data or controls on generic HRQoL. A significantly lower generic HRQoL was found for patients with HD in 4 out of 15 studies, whereas 3 out of 15 studies found a significantly higher generic HRQoL in patients. Meta-analytic aggregation showed a non-significantly impaired generic HRQoL (*d =* -0.168 [95%CI: -0.481; 0.145], *P* = 0.293, *I²* = 94.9) in patients with HD compared to healthy controls (Figure 2). Visual interpretation of the funnel plot and Egger’s test (*t* = 0.841; *P* = 0.416) suggested that there was no indication of publication bias, and the aggregated effect was also not robust with a fail safe N of 9 studies.

**Physical HRQoL:** Twelve (12) studies (*n* = 774 patients) were included in the meta-analysis comparing patients with HD to normative data or controls on physical HRQoL. A significantly lower physical HRQoL was found for patients with HD in 3 out of 12 studies, whereas 3 out of 12 studies found a significantly higher physical HRQoL in patients. Meta-analytic aggregation showed a non-significantly lower physical HRQoL (*d* = -0.042 [95%CI: -0.419; 0.335], *P* = 0.829, *I²* = 95.1) in patients with HD compared to healthy controls (Figure 2). Visual interpretation of the funnel plot and Egger’s test (*t* = 1.391; *P* = 0.194) suggested that there was no indication of publication bias, and the aggregated effect was also not robust with a fail safe N of 0 studies.

**Psychosocial HRQoL:** Thirteen (13) studies (*n* = 924 patients) were included in the meta-analysis of comparing patients with HD to normative data or controls on psychosocial HRQoL. A significantly lower psychosocial HRQoL was found for patients with HD in 6 out of 13 studies, whereas 4 out of 13 studies found a significantly higher psychosocial HRQoL in patients. Meta-analytic aggregation showed a non-significantly lower psychosocial HRQoL (*d* = -0.159 [95%CI: -0.458; 0.141], *P* = 0.299, *I²* = 93.6) in patients with HD compared to healthy controls (Figure 2). Visual interpretation of the funnel plot and Egger’s test (*t* = 0.476; *P* = 0.643) suggested that there was no indication of publication bias, and the aggregated effect was also not robust with a fail safe N of 18 studies.

**Social HRQoL:** Five (5) studies (*n* = 308 patients) were included in the meta-analysis comparing patients with HD to normative data or controls on social HRQoL. A significantly lower social HRQoL was found for patients with HD in 1 out of 5 studies, whereas 1 out of 5 studies found a significantly higher social HRQoL in patients. Meta-analytic aggregation showed a non-significantly lower social HRQoL (*d* = -0.092 [95%CI: -0.642; 0.457], *P* = 0.742, *I²* = 92.3), in patients with HD compared to healthy controls (Figure 2). Visual interpretation of the funnel plot and Egger’s test (*t* = 0.554; *P* = 0.618) suggested there was no indication of publication bias, and the aggregated effect was also not robust with a fail safe N of 0 studies.

***Patient and clinical factors explaining differences in generic HRQoL***

Table 2 summarizes the results from the subgroup analyses. Meta-analytic effects for generic HRQoL did not significantly differ between age groups. There was an influence of the type of questionnaire used, as meta-analytic aggregation of studies using the CHQ showed a significant medium-sized impairment in generic HRQoL in patients with HD compared to normative data or controls, whereas meta-analytic aggregation of studies using the TACQoL or PedsQL showed no significant differences. Meta-analytic aggregation also showed no significant differences between studies comparing patients to normative reference data and studies comparing patients with constructed control groups. The complexity of the construct of generic HRQoL was expressed by the difference that was seen when comparing the effects sizes of studies reporting generic HRQoL scores and studies for which a generic HRQoL score was derived from the average of domain scores. Meta-analytic aggregation showed a significant medium-sized impairment in generic HRQoL when only studies were included that reported generic HRQoL scores, whereas meta-analytic aggregation showed no significant effect when only studies were included in which a generic HRQoL score was constructed from the average of the reported domain scores. There was no relationship between the percentage of male patients in studies and the individual study’s effect sizes for generic HRQoL (*b* = 0.308, *P* = 0.631, *R²* = 0.00). Also the percentage of measurements with self-report in studies was not significantly associated with effect sizes for generic HRQoL (*b* = 0.331, *P* = 0.467, *R²* = 0.00). Based on the amount of observations, statistical power was too small to test the influence of age, length of aganglionosis, operation technique, postoperative complications, presence of stoma and syndromal anomalies on generic HRQoL of patients with HD.

***Disease-specific health-related quality of life***

Disease-specific HRQoL was reported in 4 studies (*n* = 252 patients). Hartman *et al*[49] only reported an overall QoL score, with 5 domain scores constructed into a single HAQL score (18.3 ± 1.7), which represented a good disease-specific HRQoL, but none of the other studies with the HAQL used this total disease-specific HRQoL score, making it impossible to compare these findings to those obtained in other studies. The domain scores of the remaining 3 studies were aggregated to construct summary estimates for the HAQL scores, of which an overview is presented in Table 3. Physical symptoms impacted disease-specific physical HRQoL negatively in all 3 studies, which is similar to the findings reported by Hanneman *et al*[4], where physical symptoms had the lowest mean rank score. Across all studies, diarrhea was the second factor to negatively impacted disease-specific HRQoL, and – to a lesser extent - fecal incontinence. The domains laxative diet, constipating diet, constipation, urinary continence, social functioning, emotional functioning and body image had no significant negative impact on disease-specific HRQoL. In summary, all studies showed an impairment on disease-specific physical HRQoL. Psychosocial and social HRQoL were not negatively influenced by disease-specific complaints in all four studies.

***Quality of the evidence***

The majority of the studies in the current systematic review were of good quality (10 out of 17 studies, 59%), whereas one study was of fair and 6 studies were of poor quality according to the NOS (Table 4). Meta-analytic estimates of generic HRQoL did not differ significantly between studies of good, fair and poor quality (*Q* = 2.220; *P* = 0.330), neither did meta-analytic estimates of physical HRQoL (*Q* = 4.391; *P* = 0.111) and psychosocial HRQoL (*Q* = 2.705; *P* = 0.259). However, meta-analytic estimates of social HRQoL did differ significantly between studies of good, fair and poor quality (*Q* = 9.285; *P* = 0.010). More specifically, social HRQoL was rated higher in the one study of low quality (*d* = 0.589 [95%CI: 0.317; 0.861], *P* < 0.001, *n* = 1), compared to those of fair and good quality.

When including only studies of good quality, meta-analytic aggregation showed a medium-sized significantly impaired generic HRQoL in patients compared to normative data or controls (*d* = -0.342 [95%CI: -0.665; -0.019], *P* = 0.038). When including only studies of good quality for psychosocial HRQoL, meta-analytic aggregation showed a medium-sized significantly impaired psychosocial HRQoL (*d* = -0.339 [95%CI: -0.656; -0.022], *P* = 0.036), whereas meta-analytic aggregation of only studies with good quality showed no significant differences between patients and normative data or controls for physical HRQoL (*d* = -0.199 [95%CI: -0.527; 0.129], *P* = 0.235) and social HRQoL (*d* = -0.322 [95%CI: -1.033; 0.390], *P* = 0.376).

**DISCUSSION**

The findings of this systematic review and meta-analysis suggest that generic HRQoL is not impaired in patients with HD compared to healthy controls and that physical HRQoL is most impaired as a result of disease-specific complaints. The high heterogeneity in HRQoL findings among the included studies implies that there are underlying factors moderating the HRQoL of patients with HD. Our findings indicated that generic HRQoL is not influenced by sex and type of respondent (parental proxy or self-report) and that generic HRQoL did not differ significantly between different age groups. The quantity of the available evidence did not allow to test for the moderating effect of length of aganglionosis, operation technique, postoperative complications, presence of a stoma and the presence of a syndromal anomalies on generic HRQoL.

Findings in several studies have shown no differences in HRQoL between male and female patients, which also corresponds to our findings[26,46-48].Furthermore, there is evidence suggesting that HRQoL varies with increasing age and is influenced by factors like coping strategies[23,48,49]and psychological changes accompanying life events, including puberty[11,16,25,26,49-54]. Adolescents may have less ability to adapt their lifestyle because of the influence of peer pressure and the wish to adapt to their peers and not be different from their peers. Adult patients and parents of patients with HD are more capable to adapt their lifestyle, which may result in better HRQoL in children and adults patients, compared to adolescent patients. Findings in previous studies have shown that parents tend to overestimate problems and impairments in patients with chronic diseases[41,55-58]. This in turn may be influenced by their cultural, social and educational background[39,46,53,59]. Also anxiety in parents of patients with HD may play an important role as well[54,60].

The severity of HD may also impact HRQoL. In this meta-analysis we could not test for the relation between length of disease and generic HRQoL. Findings from earlier studies are inconsistent[26,48,61,62], but suggest that HRQoL may not so much be dependent on length of disease itself, but with factors associated with differences in length of aganglionosis, including occurrence of obstructive defecation problems, postoperative complications and the operation technique that was used[49,53,61,63]. Also, current evidence is inconclusive on which type of the operation technique is associated with better HRQoL outcome[63-66]. Frequently reported disease-specific sequelae including obstipation[1,11,16,23,25,26,48,49,53,61,67,68], fecal incontinence[1,11,16,23,25,26,48,49,53,61,67,68] and the presence of a stoma[1,11,16,23,25,26,48,49,53,61,67] have shown to be associated with impaired HRQoL.

Previous studies have suggested that patients with HD who have an associated syndrome, may have lower HRQoL than patients with non-syndromal HD. In particular Down syndrome is known to be associated with lower QoL[29,69]. Patients with an associated syndrome unfortunately were underrepresented in the studies included in this meta-analysis, as these patients were often excluded from questionnaire surveys because of mental retardation that is associated with syndromes. Therefore, the influence of having an associated syndrome on HRQoL outcome could not be assessed in this study.

Our findings indicate that overall HRQoL estimates cannot simply be calculated by taking the average of domain scores, suggesting different weight of different aspects of health on the overall evaluation of HRQoL. This may be explained by differences in the items based on which the domain scores are constructed, which varies between questionnaires. But it may also reflect that HRQoL is a challenging multidimensional construct to measure. Some dimensions of health may have more influence on overall HRQoL than others, which may be based on the extent to which functioning in that domain is limited, but may also be under the influence of personal beliefs, goals and coping strategies.

The relationship between functional outcome and HRQoL outcome also remains subject to debate. Based on the available evidence in the current study, the relationship between functional outcome and HRQoL could not be tested. Our findings on disease-specific HRQoL suggest that some disease-specific symptoms, in particular diarrhea and fecal incontinence, may impair physical functioning of patients with HD rather than psychosocial and social functioning. Differences in outcome may be explained by differences in selection of cohorts between the few studies describing disease-specific HRQoL, as some cohorts included patients with Anorectal Malformation (ARM) and another cohort consisted only of patients with a severe form of HD: Total Colonic Aganglionosis (TCA)[61,70].

Heterogeneity in findings on generic HRQoL outcome may be explained by methodological aspects. Although we found no differences in HRQoL scores between studies that compared HRQoL findings of patients with HD to a normative cohort, and studies that compared HRQoL findings with a selected cohort of controls, sensitivity analysis showed that when aggregating only studies of good quality, overall and psychosocial HRQoL of patients with HD is significantly lower compared to healthy controls. This suggests our main findings on overall and psychosocial HRQoL may have overestimated overall and psychosocial HRQoL outcomes in patients with HD, resulting in a smaller difference compared to healthy controls.

***Strengths and limitations***

This is the first meta-analysis that summarizes the available evidence on HRQoL outcome of patients with HD. Our findings must be interpreted in the light of a few limitations. First, we could not test whether HRQoL is moderated by length of aganglionosis, operation technique, postoperative complications, presence of stoma and the presence of an associated syndrome, because of the small number of studies with complete data of study- and patient characteristics. Although for a few factors the moderation on HRQoL findings was tested in this study, this was done by meta-regression or group-comparison of meta-analytic findings. This type of analysis does not allow for the calculation of direct relations but calculates relations between studies’ averages or proportions and studies effect sizes. Second, there was large heterogeneity in HRQoL findings among the small amount of included studies, resulting in non-robust effects in this study. Third, the evidence of this meta-analysis is based on small, cross-sectional studies, which makes it impossible to assess longitudinal trends in HRQoL, and to assess the influence of transitions in life including puberty and adolescence on HRQoL. Our findings showed no linear relationship between age and HRQoL, but this relation may not be linear. The subgroup analysis did not indicate significant differences between age groups, but is limited by the randomness of the cut-off values used to group the patients into age groups. A last limitation of this meta-analysis is that different instruments to measure HRQoL make different estimations, we aimed to correct for this by including the difference of patients with Hirschsprung disease with normative data in the meta-analysis, which is less vulnerable to a bias introduced by variance between instruments than directly including scores.

***Risk of bias***

There was a risk of selection bias, as some included studies consisted of a cohort with patients with anorectal malformations and patients with Hirschsprung disease, and also because patients with Down syndrome were underrepresented. Although we tried to limit the influence of information bias by including only studies that used questionnaires that had shown to have adequate construct validity to measure HRQoL, there was heterogeneity in HRQoL outcomes assessed by the different instruments. Differences in the design of the questionnaires, the amount of detail assess with the different items and constitution of domain scores may account for this. There was no evidence of an influence of publication bias on our findings based on Egger’s intercept and visual inspection of funnelplots (presented in the Supplementary Materials), although findings were not very robust with low fail safe N’s.

**CONCLUSION**

In this systematic review and meta-analysis, no evidence was found for impaired HRQoL outcome in patients with HD compared to healthy controls, neither for the moderating effect of sex, parental proxy or self-report on HRQoL outcome. Physical functioning was most impaired by disease-specific complaints. To further study the longitudinal trends in HRQoL and determinants of HRQoL in patients with HD, we need longitudinal studies that assess the relationship between patient characteristics, functional outcomes and HRQoL.

**ARTICLE HIGHLIGHTS**

***Research background***

Patients with Hirschsprung disease are at risk for disease-specific sequelae, that in turn may impair health-related quality of life (HRQoL).

***Research motivation***

An increasing number of cohort studies describe health-related quality of life in patients with Hirschsprung disease, but no previous study has systematically reviewed and quantitatively analyzed all available evidence on HRQoL.

***Research objectives***

To summarize all available evidence on HRQoL in patients with Hirschsprung disease and to study moderating factors of HRQoL.

***Research methods***

A systematic review and meta-analysis in accordance with the PRISMA guidelines was conducted. After search in Pubmed, Web of Sciences, PsycInfo and Embase and selection, 17 studies met eligibility criteria and were included in this study. Random effect models were used for meta-analytic aggregation of generic HRQoL scores. Meta-regression was used to assess the relationship between patient and clinical characteristics and generic HRQoL. Disease-specific HRQoL outcomes of patients with HD were systematically reviewed.

***Research results***

Seventeen articles were included in the systematic review (*n* = 1137 patients) and 15 in the quantitative meta-analysis (*n* = 1024 patients). Patient’s age ranged between 0 and 21 years. Meta-analytic aggregation showed a non-significantly impaired generic HRQoL in patients with HD compared to healthy controls. Physical, psychosocial and social HRQoL were also not significantly lower compared to healthy controls. There was no relation between health-related outcomes and the sex of the patients and whether generic HRQoL was measured by parental proxy or self-report. Disease-specific complaints of patients with HD impaired physical HRQoL, but not psychosocial and social HRQoL.

***Research conclusions***

In this systematic review and meta-analysis, no evidence was found for impaired generic HRQoL in patients with HD compared to healthy controls, neither for moderating effects of sex, parental proxy or self-report.

***Research perspectives***

Future studies should focus on longitudinal trends in HRQoL and on the relation between funtional outcome and HRQoL.

**ACKNOWLEDGEMENTS**

The authors would like to thank F.S. van Etten-Jamaludin (AMC clinical librarian) for assistance during the search construction for this meta-analysis and review.

**REFERENCES**

1 **Rintala RJ**, Pakarinen MP. Outcome of anorectal malformations and Hirschsprung's disease beyond childhood. *Semin Pediatr Surg* 2010; **19**: 160-167 [PMID: 20307853 DOI: 10.1053/j.sempedsurg.2009.11.021]

2 **Kumar V,** Abbas AK, Fausto N, Aster JC. Robbins and Cotran pathologic basis of disease, professional edition e-book: elsevier health sciences, 2014 [DOI:10.1056/nejm199011153232021]

3 **Drissi F**, Meurette G, Baayen C, Wyart V, Cretolle C, Guinot A, Podevin G, Lehur PA. Long-term Outcome of Hirschsprung Disease: Impact on Quality of Life and Social Condition at Adult Age. *Dis Colon Rectum* 2019; **62**: 727-732 [PMID: 30807458 DOI: 10.1097/DCR.0000000000001363]

4 **Hanneman MJ**, Sprangers MA, De Mik EL, Ernest van Heurn LW, De Langen ZJ, Looyaard N, Madern GC, Rieu PN, van der Zee DC, van Silfhout M, Aronson DC. Quality of life in patients with anorectal malformation or Hirschsprung's disease: development of a disease-specific questionnaire. *Dis Colon Rectum* 2001; **44**: 1650-1660 [PMID: 11711738 DOI: 10.1007/BF02234386]

5 **Mattei P. Fundamentals of pediatric surgery: Springer Science & Business Media,** 2011 [DOI:10.1007/978-1-4419-6643-8]

6 **Bai Y**, Chen H, Hao J, Huang Y, Wang W. Long-term outcome and quality of life after the Swenson procedure for Hirschsprung's disease. *J Pediatr Surg* 2002; **37**: 639-642 [PMID: 11912526 DOI: 10.1053/jpsu.2002.31625]

7 **Diseth TH**, Bjørnland K, Nøvik TS, Emblem R. Bowel function, mental health, and psychosocial function in adolescents with Hirschsprung's disease. *Arch Dis Child* 1997; **76**: 100-106 [PMID: 9068296 DOI: 10.1136/adc.76.2.100]

8 **Heikkinen M**, Rintala R, Luukkonen P. Long-term anal sphincter performance after surgery for Hirschsprung's disease. *J Pediatr Surg* 1997; **32**: 1443-1446 [PMID: 9349764 DOI: 10.1016/s0022-3468(97)90557-1]

9 **Marty TL**, Seo T, Matlak ME, Sullivan JJ, Black RE, Johnson DG. Gastrointestinal function after surgical correction of Hirschsprung's disease: long-term follow-up in 135 patients. *J Pediatr Surg* 1995; **30**: 655-658 [PMID: 7623220 DOI: 10.1016/0022-3468(95)90682-7]

10 **Pruitt LCC**, Skarda DE, Rollins MD, Bucher BT. Hirschsprung-associated enterocolitis in children treated at US children's hospitals. *J Pediatr Surg* 2020; **55**: 535-540 [PMID: 31836243 DOI: 10.1016/j.jpedsurg.2019.10.060]

11 **Yanchar NL**, Soucy P. Long-term outcome after Hirschsprung's disease: patients' perspectives. *J Pediatr Surg* 1999; **34**: 1152-1160 [PMID: 10442612 DOI: 10.1016/s0022-3468(99)90588-2]

12 Group TW. The World Health Organization Quality of Life Assessment (WHOQOL). Development and psychometric properties. Social Science and Medicine 1998; 46: 1569-1585

13 **Prevention CfDCa. Measuring healthy days: Population assessment of health-related quality of life. . Atlanta,** Georgia: Centers for Disease Control and Prevention, 2000 [DOI:10.1037/e372122004-001]

14 **Solans M**, Pane S, Estrada MD, Serra-Sutton V, Berra S, Herdman M, Alonso J, Rajmil L. Health-related quality of life measurement in children and adolescents: a systematic review of generic and disease-specific instruments. *Value Health* 2008; **11**: 742-764 [PMID: 18179668 DOI: 10.1111/j.1524-4733.2007.00293.x]

15 **Granström AL**, Danielson J, Husberg B, Nordenskjöld A, Wester T. Adult outcomes after surgery for Hirschsprung's disease: Evaluation of bowel function and quality of life. *J Pediatr Surg* 2015; **50**: 1865-1869 [PMID: 26164226 DOI: 10.1016/j.jpedsurg.2015.06.014]

16 **Jarvi K**, Laitakari EM, Koivusalo A, Rintala RJ, Pakarinen MP. Bowel function and gastrointestinal quality of life among adults operated for Hirschsprung disease during childhood: a population-based study. *Ann Surg* 2010; **252**: 977-981 [PMID: 21107107 DOI: 10.1097/SLA.0b013e3182018542]

17 **Meinds RJ**, van der Steeg AFW, Sloots CEJ, Witvliet MJ, de Blaauw I, van Gemert WG, Trzpis M, Broens PMA. Long-term functional outcomes and quality of life in patients with Hirschsprung's disease. *Br J Surg* 2019; **106**: 499-507 [PMID: 30653654 DOI: 10.1002/bjs.11059]

18 **Raat H**, Mohangoo AD, Grootenhuis MA. Pediatric health-related quality of life questionnaires in clinical trials. *Curr Opin Allergy Clin Immunol* 2006; **6**: 180-185 [PMID: 16670511 DOI: 10.1097/01.all.0000225157.67897.c2]

19 **Ludman L**, Spitz L, Tsuji H, Pierro A. Hirschsprung's disease: functional and psychological follow up comparing total colonic and rectosigmoid aganglionosis. *Arch Dis Child* 2002; **86**: 348-351 [PMID: 11970929 DOI: 10.1136/adc.86.5.348]

20 **Catto-Smith AG**, Trajanovska M, Taylor RG. Long-term continence after surgery for Hirschsprung's disease. *J Gastroenterol Hepatol* 2007; **22**: 2273-2282 [PMID: 18031392 DOI: 10.1111/j.1440-1746.2006.04750.x]

21 **Espeso L,** Coutable A, Flaum V, Rebeuh J, Lavrand F, Podevin G, Lamireau T, Enaud R, Talon I. Persistent Soiling Affects Quality of Life in Children With Hirschsprung's Disease. J Pediatr Gastroenterol Nutr 2019 [DOI:10.1097/mpg.0000000000002564]

22 **Chhabra S,** Kenny SE. Hirschsprung's disease. Surgery (Oxford) 2016; 34(12): 628-632

23 **Neuvonen MI**, Kyrklund K, Rintala RJ, Pakarinen MP. Bowel Function and Quality of Life After Transanal Endorectal Pull-through for Hirschsprung Disease: Controlled Outcomes up to Adulthood. *Ann Surg* 2017; **265**: 622-629 [PMID: 28169931 DOI: 10.1097/SLA.0000000000001695]

24 **Gunnarsdóttir A**, Sandblom G, Arnbjörnsson E, Larsson LT. Quality of life in adults operated on for Hirschsprung disease in childhood. *J Pediatr Gastroenterol Nutr* 2010; **51**: 160-166 [PMID: 20453676 DOI: 10.1097/MPG.0b013e3181cac1b6]

25 **Mills JL**, Konkin DE, Milner R, Penner JG, Langer M, Webber EM. Long-term bowel function and quality of life in children with Hirschsprung's disease. *J Pediatr Surg* 2008; **43**: 899-905 [PMID: 18485963 DOI: 10.1016/j.jpedsurg.2007.12.038]

26 **Collins L**, Collis B, Trajanovska M, Khanal R, Hutson JM, Teague WJ, King SK. Quality of life outcomes in children with Hirschsprung disease. *J Pediatr Surg* 2017; **52**: 2006-2010 [PMID: 28927976 DOI: 10.1016/j.jpedsurg.2017.08.043]

27 **Brown H**, Randle J. Living with a stoma: a review of the literature. *J Clin Nurs* 2005; **14**: 74-81 [PMID: 15656851 DOI: 10.1111/j.1365-2702.2004.00945.x]

28 **Danielsen AK**, Rosenberg J. Health related quality of life may increase when patients with a stoma attend patient education--a case-control study. *PLoS One* 2014; **9**: e90354 [PMID: 24609004 DOI: 10.1371/journal.pone.0090354]

29 **Friedmacher F**, Puri P. Hirschsprung's disease associated with Down syndrome: a meta-analysis of incidence, functional outcomes and mortality. *Pediatr Surg Int* 2013; **29**: 937-946 [PMID: 23943251 DOI: 10.1007/s00383-013-3361-1]

30 **Moher D**, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; **6**: e1000097 [PMID: 19621072 DOI: 10.1371/journal.pmed.1000097]

31 Covidence – better systematic review management. 2020

32 **Wan X,** Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology 2014; 14(1): 135 [DOI: 10.1186/1471-2288-14-135]

33 **Luo D**, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. *Stat Methods Med Res* 2018; **27**: 1785-1805 [PMID: 27683581 DOI: 10.1177/0962280216669183]

34 **Fekkes M,** Bruil J, Vogels T. TAPQOL-manual: Developed by Leiden Center for Child Health and Pediatrics LUMC-TNO. 2004 [DOI:10.5171/2014.913057]

35 **Varni JW,** Limbers CA, Burwinkle TM. Parent proxy-report of their children's health-related quality of life: an analysis of 13,878 parents' reliability and validity across age subgroups using the PedsQL™ 4.0 Generic Core Scales. Health and quality of life outcomes 2007; 5(1): 2 [DOI:10.1186/1477-7525-5-2]

36 **Varni JW**, Limbers CA, Neighbors K, Schulz K, Lieu JE, Heffer RW, Tuzinkiewicz K, Mangione-Smith R, Zimmerman JJ, Alonso EM. The PedsQL™ Infant Scales: feasibility, internal consistency reliability, and validity in healthy and ill infants. *Qual Life Res* 2011; **20**: 45-55 [PMID: 20730626 DOI: 10.1007/s11136-010-9730-5]

37 **Vogels T,** Bruil J, Koopman H, Fekkes M, Verrips G. TACQOL CF 12-15 Manual. Leiden: TNO Prevention and Health 2004 [DOI:10.1023/a:1008848218806]

38 **Vogels T,** Verrips G, Koopman H, Theunissen N, Fekkes M, Kamphuis R. TACQOL manual: parent form and child form. Leiden Center for Child Health and Pediatrics; TNO, 2000 [DOI:10.1023/a:1008848218806]

39 **Varni JW**, Burwinkle TM, Seid M, Skarr D. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. *Ambul Pediatr* 2003; **3**: 329-341 [PMID: 14616041 DOI: 10.1367/1539-4409(2003)003<0329:tpaapp>2.0.co;2]

40 **Wells G,** Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. Newcastle-Ottawa quality assessment scale cohort studies. 2014. 2019 [DOI:10.7717/peerj.8815/supp-4]

41 **Berkman ND**, Lohr KN, Ansari M, McDonagh M, Balk E, Whitlock E, Reston J, Bass E, Butler M, Gartlehner G, Hartling L, Kane R, McPheeters M, Morgan L, Morton SC, Viswanathan M, Sista P, Chang S. Grading the Strength of a Body of Evidence When Assessing Health Care Interventions for the Effective Health Care Program of the Agency for Healthcare Research and Quality: An Update. 2013 Nov 18. In: Methods Guide for Effectiveness and Comparative Effectiveness Reviews [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008– [PMID: 24404627]

42 **Borenstein M,** Hedges L, Higgins J, Rothstein H. Comprehensive meta-analysis version 3. Englewood NJ: Biostat. Inc, 2005 [DOI:10.1177/1094428106296641]

43 **Cohen J. Statistical power analysis for the behavioral sciences: Academic press,** 2013 [DOI:10.4324/9780203771587]

44 **Higgins JP,** Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in medicine 2002; 21(11): 1539-1558

45 **Card NA. Applied meta-analysis for social science research: Guilford Publications,** 2015 [DOI:10.1111/insr.12011\_17]

46 **Çavusoglu YH,** Yagiz B, Karaman A, Karaman I, Özgüner IF. The Perception of the Quality of Life in Turkish Children Who Have Undergone Surgical Correction of a Congenital Gastrointestinal and Abdominal Anomaly/Dogumsal Gastrointestinal ve Abdominal Anomalisi Cerrahi Olarak Düzeltilmis Türk Çocuklarinda Yasam Kalitesi Algisi. Türkiye Klinikleri Tip Bilimleri Dergisi 2012; 32(4): 1004 [DOI:10.5336/medsci.2011-26391]

47 **Khalil M**. Long-term health-related quality of life for patients with Hirschsprung's disease at 5 years after transanal endorectal pull-through operation. *Qual Life Res* 2015; **24**: 2733-2738 [PMID: 25966664 DOI: 10.1007/s11136-015-1012-9]

48 **Sood S**, Lim R, Collins L, Trajanovska M, Hutson JM, Teague WJ, King SK. The long-term quality of life outcomes in adolescents with Hirschsprung disease. *J Pediatr Surg* 2018; **53**: 2430-2434 [PMID: 30244941 DOI: 10.1016/j.jpedsurg.2018.08.036]

49 **Hartman EE**, Oort FJ, Sprangers MA, Hanneman MJ, van Heurn LW, de Langen ZJ, Madern GC, Rieu PN, van der Zee DC, Looyaard N, van Silfhout-Bezemer M, Aronson DC. Factors affecting quality of life of children and adolescents with anorectal malformations or Hirschsprung disease. *J Pediatr Gastroenterol Nutr* 2008; **47**: 463-471 [PMID: 18852639 DOI: 10.1097/MPG.0b013e31815ce545]

50 **Amin R**, Knezevich M, Lingongo M, Szabo A, Yin Z, Oldham KT, Calkins CM, Sato TT, Arca MJ. Long-term Quality of Life in Neonatal Surgical Disease. *Ann Surg* 2018; **268**: 497-505 [PMID: 29994930 DOI: 10.1097/SLA.0000000000002918]

51 **Broderick PC**, Jennings PA. Mindfulness for adolescents: a promising approach to supporting emotion regulation and preventing risky behavior. *New Dir Youth Dev* 2012; **2012**: 111-126, 11 [PMID: 23359447 DOI: 10.1002/yd.20042]

52 **Grano C**, Fernandes M, Aminoff D, Bucci S, Lucidi F, Violani C. The role of coping strategies on health-related quality of life in adults with anorectal malformations. *Pediatr Surg Int* 2016; **32**: 759-765 [PMID: 27369966 DOI: 10.1007/s00383-016-3911-4]

53 **Hartman EE**, Oort FJ, Aronson DC, Hanneman MJ, van Heurn E, de Langen ZJ, Madern GC, Rieu PN, van der Zee DC, Looyaard N, van Silfhout-Bezemer M, Sprangers MA. Explaining change in quality of life of children and adolescents with anorectal malformations or Hirschsprung disease. *Pediatrics* 2007; **119**: e374-e383 [PMID: 17272599 DOI: 10.1542/peds.2006-0212]

54 **Svetanoff WJ,** Kapalu CL, Lopez JJ, Fraser JA, Briggs KB, Rentea RM. Psychosocial factors affecting quality of life in patients with anorectal malformation and Hirschsprung disease-a qualitative systematic review. Journal of pediatric surgery 2021 [DOI:10.1016/j.jpedsurg.2021.05.004]

55 **Lambert LM**, Minich LL, Newburger JW, Lu M, Pemberton VL, McGrath EA, Atz AM, Xu M, Radojewski E, Servedio D, McCrindle BW; Pediatric Heart Network Investigators. Parent- *vs* child-reported functional health status after the Fontan procedure. *Pediatrics* 2009; **124**: e942-e949 [PMID: 19841109 DOI: 10.1542/peds.2008-1697]

56 **Loonen HJ**, Derkx BH, Koopman HM, Heymans HS. Are parents able to rate the symptoms and quality of life of their offspring with IBD? *Inflamm Bowel Dis* 2002; **8**: 270-276 [PMID: 12131611 DOI: 10.1097/00054725-200207000-00006]

57 **Ooi DSQ,** Loke KY, Ho CWL, Lim YY, Tay V, Karuppiah V, Sng AA, Lai LY, Lee YS, Griva K. Self and parent-proxy rated health-related quality of life (HRQoL) in youth with obesity: are parents good surrogates? Qual Life Res 2020 [DOI:10.1007/s11136-020-02472-y]

58 **Weaver MS**, Hanna R, Hetzel S, Patterson K, Yuroff A, Sund S, Schultz M, Schroth M, Halanski MA. A Prospective, Crossover Survey Study of Child- and Proxy-Reported Quality of Life According to Spinal Muscular Atrophy Type and Medical Interventions. *J Child Neurol* 2020; **35**: 322-330 [PMID: 32009500 DOI: 10.1177/0883073819900463]

59 **Hack M**. Consideration of the use of health status, functional outcome, and quality-of-life to monitor neonatal intensive care practice. *Pediatrics* 1999; **103**: 319-328 [PMID: 9917474]

60 **Witvliet MJ**, Bakx R, Zwaveling S, van Dijk TH, van der Steeg AF. Quality of Life and Anxiety in Parents of Children with an Anorectal Malformation or Hirschsprung Disease: The First Year after Diagnosis. *Eur J Pediatr Surg* 2016; **26**: 2-6 [PMID: 26382660 DOI: 10.1055/s-0035-1559885]

61 **Roorda D**, Witvliet MJ, Wellens LM, Schulten DV, Sloots CEJ, de Blaauw I, Broens PMA, Oosterlaan J, van Heurn LWE, van der Steeg AFW. Long-term outcome and quality of life in patients with total colonic aganglionosis in the Netherlands. *Colorectal Dis* 2018; **20**: 719-726 [PMID: 29543374 DOI: 10.1111/codi.14095]

62 **Swenson O**, Sherman JO, Fisher JH, Cohen E. The treatment and postoperative complications of congenital megacolon: A 25 year followup. *Ann Surg* 1975; **182**: 266-273 [PMID: 1164055 DOI: 10.1097/00000658-197509000-00008]

63 **Saysoo MR**, Dewi FST, Gunadi. Quality of life of patients with Hirschsprung disease after Duhamel and Soave pull-through procedures: A mixed-methods sequential explanatory cohort study. *Ann Med Surg (Lond)* 2020; **56**: 34-37 [PMID: 32577229 DOI: 10.1016/j.amsu.2020.05.043]

64 **Gosemann JH**, Friedmacher F, Ure B, Lacher M. Open *vs* transanal pull-through for Hirschsprung disease: a systematic review of long-term outcome. *Eur J Pediatr Surg* 2013; **23**: 94-102 [PMID: 23572464 DOI: 10.1055/s-0033-1343085]

65 **Seo S**, Miyake H, Hock A, Koike Y, Yong C, Lee C, Li B, Pierro A. Duhamel and Transanal Endorectal Pull-throughs for Hirschsprung' Disease: A Systematic Review and Meta-analysis. *Eur J Pediatr Surg* 2018; **28**: 81-88 [PMID: 28958095 DOI: 10.1055/s-0037-1607061]

66 **Tannuri AC**, Ferreira MA, Mathias AL, Tannuri U. Long-term results of the Duhamel technique are superior to those of the transanal pullthrough: A study of fecal continence and quality of life. *J Pediatr Surg* 2017; **52**: 449-453 [PMID: 27836370 DOI: 10.1016/j.jpedsurg.2016.10.007]

67 **Townley OG**, Lindley RM, Cohen MC, Murthi GV. Functional outcome, quality of life, and 'failures' following pull-through surgery for hirschsprung's disease: A review of practice at a single-center. *J Pediatr Surg* 2020; **55**: 273-277 [PMID: 31759654 DOI: 10.1016/j.jpedsurg.2019.10.042]

68 **Loganathan AK**, Mathew AS, Kurian JJ. Assessment of Quality of Life and Functional Outcomes of Operated Cases of Hirschsprung Disease in a Developing Country. *Pediatr Gastroenterol Hepatol Nutr* 2021; **24**: 145-153 [PMID: 33833970 DOI: 10.5223/pghn.2021.24.2.145]

69 **Haddad F**, Bourke J, Wong K, Leonard H. An investigation of the determinants of quality of life in adolescents and young adults with Down syndrome. *PLoS One* 2018; **13**: e0197394 [PMID: 29897903 DOI: 10.1371/journal.pone.0197394]

70 **Baayen C**, Feuillet F, Clermidi P, Crétolle C, Sarnacki S, Podevin G, Hardouin JB. Validation of the French versions of the Hirschsprung's disease and Anorectal malformations Quality of Life (HAQL) questionnaires for adolescents and adults. *Health Qual Life Outcomes* 2017; **15**: 24 [PMID: 28129770 DOI: 10.1186/s12955-017-0599-7]

**Footnotes**

**Conflict-of-interest statement:** All authors have no conflict of interest to disclose.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** June 9, 2021

**First decision:** October 3, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Netherlands

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Lourencao P, Sergi CM **S-Editor:** Wang LL **L-Editor:** A **P-Editor:** Wang LL

**Figure Legends**



**Figure 1 PRISMA flowchart of study selection.**



**Figure 2 Forest plots of total health-related quality of life (HRQoL), physical HRQoL, psychosocial HRQoL and social HRQoL of patients with Hirschsprung disease compared to normative data.**

**Table 1 Characteristics of included studies**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study design** | **Sample size** | **Self- report** | **Parental proxy report** | **HRQoL instrument** | **Age range** **(yr)** | **Mean age (yr)** | **Sex** **(% male)** | **Operation-****technique**  | **Segment- length** **(% short)** | **Syndromal comorbidity (%)** | **Stoma present (%)** | **Postoperative complications (%)** |
| Amin *et al*[67], 2018 | Cohort | 46 | 0 | 46 | PedsQL | 0-18 | 4.2 | 71 |   | 80 |   |   |   |
| Baayen *et al*[81], 2017 | Cohort | 50 | 50 | 0 | HAQL | 12-16 |   |   |   |   |   | 6 |   |
| Cavusoglu *et al*[61], 2012 | Case-control | 12 | 6 | 12 | PedsQL | 2-12 | 4.7 | 84 |   |   |   |   |   |
| Collins *et al*[27], 2017 | Cohort | 60 | 0 | 60 | PedsQL | 2-10 | 6.4 | 82 | 13% Duhamel 80% Trans- anal PT | 78 | 12 | 13 |   |
| Espeso *et al*[22], 2019 | Cohort | 63 |   |   | HAQL | 6-18 | 10.8 | 70 | 22% Duhamel 78% Trans- anal PT | 79 | 0 | 0 | 44 |
| Hartman *et al*[12], 2007 | Cohort | 121 | 121 | 0 | HAQL / TACQoL | 8-16 | 11.4 | 82 |   | 69 | 0 | 4 |   |
| Hartman *et al*[64], 2008 | Cohort | 152 | 152 | 0 | TACQoL | 8-16 | 11.6 | 80 |   | 68 | 0 | 3 |   |
| Khalil *et al*[62], 2015 | Cohort | 53 | 0 | 53 | PedsQL | 5-7 | 5.9 | 70 |   |   |   |   | 3 |
| Lane *et al*[13], 2016 | Cohort | 118 | 0 | 118 | PedsQL | 0-17 |   |   |   |   |   |   |   |
| Meinds *et al*[18], 2019 | Cohort | 150 | 0 | 150 | CHQ-CF87 | 8-17 |   | 79 | 62% Duhamel 16% Trans- anal PT | 84 |   | 0 | 31 |
| Mills *et al*[26], 2008 | Cohort | 51 | 37 | 44 | PedsQL | 3-21 | 9.8 | 82 | 15% Duhamel 77% Trans- anal PT | 66 | 6 |   |   |
| Nah *et al*[14], 2018 | Case-control | 44 | 21 | 42 | PedsQL | 2-20 | 9.1 | 75 |   | 73 |   |   |   |
| Neuvonen *et al*[24], 2017 | Case-control | 39 | 27 | 12 | PedsQL | 0-17 |   | 75 | 96% Trans- anal PT | 84 | 24 | 5 | 47 |
| Roorda *et al*[74], 2018 | Cohort | 18 /14  | 7 | 7 | HAQL / CHQ-CF87 / CHQ-PF50  | 4-17 |   | 77 | 67% Duhamel | 0 | 13 | 6 |   |
| Sood *et al*[63], 2018 | Cohort | 58 | 38 | 58 | PedsQL | 11-18 | 14.5 | 84 | 7% Duhamel 86% Trans- anal PT |  84 | 12 | 7 | 28 |
| Townley *et al*[79], 2019 | Cohort | 56 | 0 | 56 | PedsQL | 0-13 | 5.4 | 80 | 84% Duhamel 16% Trans- anal PT | 77 |   | 14 |   |
| Xi *et al*[82], 2018 | Case-control | 50 | 0 | 50 | TACQoL | 6 | 6.0 | 76 | 100% Trans- anal PT |   |   |   |   |

HRQoL: Health-related quality of life; HAQL: Hirschsprung disease/anorectal malformation quality of life.

**Table 2 Differences in health-related quality of life scores in subgroup analyses**

|  |  |  |
| --- | --- | --- |
|  **Factor associated with HRQoL** | **Cohen’s d [95%CI], *P* value**1 | ***Q* value, *P* value**2 |
| Age | [0-12 yr] | *d* = -0.206 [-0.721, 0.310], *P* = 0.434 | Q = 1.727, *P* = 0.422 |
| [12-16 yr] | *d* = 0.609 [-0.492, 1.711], *P* = 0.278 |
| [16+ yr] | *d* = -0.033 [-1.170, 1.103], *P* = 0.954 |
| Type of questionnaire | PedsQL | *d* = -0.043 [-0.281, 0.195], *P* = 0.724 | Q = 6.370, *P* = 0.041a |
| TACQoL | *d* = -0.562 [-2.271, 1.147], *P* = 0.519 |
| CHQ-CF87 | *d* = -0.412 [-0.575,-0.249], *P* < 0.001b |
| Reference data | Normative scores | *d* = 0.028 [-0.278, 0.334], *P* = 0.859 | Q = 1.768, *P* = 0.184 |
| Selected controls | *d* = -0.793 [-1.965, 0.378], *P* = 0.184 |
| Overall HRQoL scores | Reported overall HRQoL scores | *d* = -0.440 [-0.817,-0.063], *P* = 0.022a | Q = 4.078, *P* = 0.043a  |
| Constructed overall HRQoL scores | *d* = 0.245 [-0.303, 0.792], *P* = 0.381 |

1The difference in scores between patients with Hirschsprung disease and normative or control groups was calculated for each study and expressed as the standardized difference in means (Cohen’s d) and aggregated across studies.

2A Q-test was done to test for significant heterogeneity between groups.

a*P* < 0.05.

b*P* < 0.01. HRQoL: Health-related quality of life.

**Table 3 Summary estimates Hirschsprung disease / Anorectal malformation Quality of Life scores**

|  |  |  |
| --- | --- | --- |
| **Summary estimates** **HAQL scores** | **Aggregated HAQL domain scores[22,74,81],1** | **Hanneman *et al***[4]**, 2001** |
| Domain | Mean (SD) | Mean rank |
| Laxative diet | 88.41 (19.63) | 64.67 |
| Constipating diet | 91.67 (17.39) | 63.77 |
| Diarrhea  | 73.32 (26.86) | 61.22 |
| Constipation | 83.33 (36.51) | 64.75 |
| Urinary continence | 94.82 (13.57) | 65.72 |
| Fecal incontinence | 78.70 (24.47) | 68.58 |
| Social functioning | 93.77 (15.40) | 65.33 |
| Emotional functioning | 84.42 (19.92) | 65.11 |
| Body image | 84.70 (20.08) | 65.48 |
| Physical symptoms | 69.33 (19.09) | 58.52 |

1The average of mean scores was calculated across domain scores of each studies and aggregated into a weighted mean (SD). HAQL: Hirschsprung disease/anorectal malformation quality of life.

**Table 4 Study quality assessment according to the Newcastle-Ottawa Scale criteria**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Selection** | **Comparability** | **Outcome** | **Assessment** |
| Amin *et al*[67], 2018 | 2 points |   | 2 points | Poor |
| Baayen *et al*[81], 2017 | 1 point |   | 2 points | Poor |
| Cavusoglu *et al*[61], 2012 | 3 points | 2 points | 2 points | Good |
| Collins *et al*[27], 2017 | 3 points | 1 point | 3 points | Good |
| Espeso *et al*[22], 2019 | 1 point |   | 2 points | Poor |
| Hartman *et al*[12], 2007 | 2 points |   | 2 points | Poor |
| Hartman *et al*[64], 2008 | 3 points | 1 point | 3 points | Good |
| Khalil *et al*[62], 2015 | 2 points |   | 3 points | Poor |
| Lane *et al*[13], 2016 | 2 points |   | 3 points | Poor |
| Meinds *et al*[18], 2019 | 3 points | 1 point | 2 points | Good |
| Mills *et al*[26], 2008 | 3 points | 1 point | 2 points | Good |
| Nah *et al*[14], 2018 | 3 points | 2 points | 2 points | Good |
| Neuvonen *et al*[24], 2017 | 3 points | 2 points | 2 points | Good |
| Roorda *et al*[74], 2018 | 2 points | 1 point | 2 points | Fair |
| Sood *et al*[63], 2018 | 3 points | 1 point | 3 points | Good |
| Townley *et al*[79], 2019 | 3 points | 1 point | 3 points | Good |
| Xi *et al*[82], 2018 | 3 points | 2 points | 3 points | Good |